Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
A vendor name, not a studied molecule: PubMed returns no papers, ClinicalTrials.gov no trials, and the registries no record for “pentadeca arginate”.
Also known as: PDA · PDA peptide · BPC-157 arginate · pentadecapeptide arginate
Part of the Repair & recovery peptides cluster
Overview
Pentadeca arginate (PDA) is a grey-market name for BPC-157 supplied as an arginate salt — the same 15-residue peptide paired with arginine as its counter-ion instead of acetate. No paper indexed in PubMed, no registered clinical trial and no entry in PubChem or the IUPHAR Guide to Pharmacology exists under the name; every claim made for it is borrowed from BPC-157's rodent literature. It is not approved anywhere.
Source & context
Biological / chemical source: Grey-market product name; the peptide component is described by sellers as BPC-157 with arginine as the counter-ion
Primary research or clinical context: Research compound, not approved anywhere; no indexed literature exists under this name
What the name refers to
“Pentadeca arginate”, usually shortened to PDA, is a product name that appeared in the research-peptide market in 2024–2025. Sellers describe it as BPC-157 — the 15-residue synthetic fragment related to a gastric protein, profiled separately on this site — formulated as an arginate salt rather than the acetate salt in which the peptide is normally supplied. “Pentadeca” refers to the fifteen residues; “arginate” to arginine as the counter-ion. Nothing else about the product is defined by the name: the peptide sequence, purity, and the ratio of arginine to peptide are whatever a given vendor states on the label.
What the literature contains: nothing
A PubMed search for the name returns no papers. ClinicalTrials.gov lists no study. PubChem has no compound record, and the IUPHAR/BPS Guide to Pharmacology has no ligand entry. This is unusual even for grey-market peptides — BPC-157, TB-500 and GHK-Cu all have literature — and it means there is no independent source for any property of pentadeca arginate: not its stability, its pharmacokinetics, its activity in animals, or its safety. Claims that the arginate form is “more stable” or “more bioavailable” than BPC-157 acetate come from sellers, not from studies.
Why a salt form would, and would not, matter
A salt changes how a peptide dissolves, how it stores as a powder and how it behaves in solution; it does not change the peptide chain itself. If PDA is what sellers say it is, its biology after dissolution is BPC-157's biology, and the arginine counter-ion would be present at a small fraction of the free amino acid in an ordinary meal. Whether the arginate salt is actually more stable than the acetate is a testable formulation question — and no test has been published. Marketing the salt as a distinct compound with distinct effects is not supported by anything in the literature.
What is known about the parent peptide
Because PDA borrows its evidence from BPC-157, the honest summary of PDA's evidence is the summary of BPC-157's: a large rodent literature on tendon, muscle, ligament and gut injury models, almost entirely from one research group; mechanistic proposals around nitric oxide signalling and angiogenesis; and, in humans, no completed efficacy trial and a single small oral safety study. In September 2023 the US FDA placed BPC-157 in the category of bulk substances that may not be used in compounding, citing safety concerns and lack of data. The BPC-157 profile lists the primary references.
Why the renaming happened
The arrival of a new name for an old peptide followed the FDA's 2023 compounding decision and the wave of enforcement letters that accompanied it. A product sold as “pentadeca arginate” is harder to match against lists that name BPC-157, and sellers can present it as a new compound. Readers should treat the two names as the same peptide for every purpose that matters — evidence, legality and safety — and should notice that the renaming added no data.
Regulatory status and what this page is not
Pentadeca arginate is not approved for any use in any jurisdiction, and the peptide it contains is barred from US compounding. Selling it for human use is illegal in the US, Canada and the EU regardless of a research label. No pharmacokinetic, safety or efficacy data exist for the salt in any species. This profile exists to record that absence plainly; it is not guidance on obtaining or using any product, and it is not medical advice.
Structure & chemistry
Molecular identity & reference confidence
Reference mass unavailable
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Described by sellers as the 15-residue BPC-157 sequence with arginine as the salt counter-ion
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- Backbone
- Described by sellers as the 15-residue BPC-157 sequence with arginine as the salt counter-ion
- Status
- Not approved anywhere; no regulatory or registry record exists under this name (September 2026)
Chemistry values: curated profile.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- EditorialProfile content reviewed and updated by the editorial team.
FAQ about Pentadeca arginate (PDA)
What is Pentadeca arginate (PDA)?+
Pentadeca arginate (PDA) is a grey-market name for BPC-157 supplied as an arginate salt — the same 15-residue peptide paired with arginine as its counter-ion instead of acetate. No paper indexed in PubMed, no registered clinical trial and no entry in PubChem or the IUPHAR Guide to Pharmacology exists under the name; every claim made for it is borrowed from BPC-157's rodent literature. It is not approved anywhere.
What Canadian product status is recorded for Pentadeca arginate (PDA)?+
Canadian product status for Pentadeca arginate (PDA) has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Pentadeca arginate (PDA)?+
Pentadeca arginate (PDA) is commonly described as approximately 15 amino acids (Research compound — salt form of a 15-residue synthetic peptide).
What is pentadeca arginate?+
A grey-market product name for BPC-157 supplied as an arginate salt. The name describes a 15-residue peptide with arginine as its counter-ion, not a new molecule.
Is pentadeca arginate the same as BPC-157?+
According to sellers, yes — the same peptide with a different salt. No independent source has characterised the product, so even that cannot be verified.
Is there any research on pentadeca arginate?+
No. PubMed, ClinicalTrials.gov, PubChem and the IUPHAR Guide to Pharmacology have no record under the name. All claims are transferred from BPC-157's rodent studies.
Is pentadeca arginate approved or legal?+
It is not approved anywhere, and BPC-157 was barred from US compounding in September 2023. Marketing it for human use is illegal in the US, Canada and the EU.
Is the arginate form more stable than BPC-157 acetate?+
That is a formulation claim made by sellers. No published study has tested it.
Further reading
- ComparisonBPC-157 vs TB-500: Differences, Research Context & ComparisonSide-by-side educational comparison of BPC-157 and TB-500—sequences, research themes, stacking discussions, and evidence limits.
- Recovery peptidesBPC-157: Oral vs Injectable — What the Research Actually ShowsThe oral-versus-injectable question for BPC-157, framed by what preclinical research actually reports about stability, gut effects, and systemic exposure. Educational only, not a protocol.
- Blends explainedWhat Is the “Wolverine” Peptide? BPC-157 + TB-500, and What the Evidence Actually Shows“Wolverine peptide” (or “Wolverine stack”) is a vendor nickname for BPC-157 combined with TB-500. This guide explains what each component is, what has actually been studied in humans (very little), what a rat combination study found and what remains untested in humans, and where it stands legally.
- FoundationsWhat Are Research Peptides? A Clear Educational GuideLearn what “research peptides” means, how they differ from approved peptide drugs, quality markers (COA, purity), and how to study them responsibly.
- SafetyPeptide Safety and Risks: A Balanced Educational OverviewAn objective, balanced overview of what research does and does not establish about peptide risks—unknowns, purity and contamination concerns, and why unapproved compounds carry uncertainty. Not reassurance and not medical advice.